CORRESPONDENCE Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans Florian B. Mayr, Victor B. Talisa, Obaid Shaikh, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMc2200415 TO THE EDITOR: Vaccine effectiveness against coronavirus disease 2019 (Covid-19) wanes over time, and boosters are now recommended for residents of the United States starting at the age of 12 years.1 Clinical trials have shown that receipt of a booster that...

ARTICLES| VOLUME 399, ISSUE 10325, P656-664, FEBRUARY 12, 2022 A three-step support strategy for relatives of patients dying in the intensive care unit: a cluster randomised trial Nancy Kentish-Barnes, Sylvie Chevret, Sandrine Valade, et al Lancet 2022; 399: 656-664 Summary Background In relatives of patients dying in intensive care units (ICUs), inadequate team support can increase the prevalence of prolonged grief and other psychological...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OPEN ACCESS ~ Consensus and Expert RecommendationBasic ultrasound head-to-toe skills for intensivists in the general and neuro intensive care unit population: consensus and expert recommendations of the European Society of Intensive Care MedicineRobba C. et al. Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trialBohé J. et al. OriginalDexametha...

ORIGINAL ARTICLE Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S Jerald Sadoff, Glenda Gray, An Vandebosch, et al N Engl J Med February 9, 2022DOI: 10.1056/NEJMoa2117608 Abstract BACKGROUND The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS We conducted the final analysis in the double-blind phase of o...

Research Letter December 30, 2021 Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves Caroline Maslo, Richard Friedland, Mande Toubkin, et al JAMA. Published online December 30, 2021. doi:10.1001/jama.2021.24868 On November 24, 2021, a SARS-CoV-2 variant of concern, Omicron (B.1.1.529), was identified in South Africa as responsible ...

ORIGINAL ARTICLE Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner, et al N Engl J Med February 16, 2022DOI: 10.1056/NEJMoa2118542 Abstract BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized...

ORIGINAL ARTICLE Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, et al N Engl J Med 2022; 386:531-543DOI: 10.1056/NEJMoa2116185 Abstract BACKGROUND NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b–3 trials in the United Kingdom and South Af...

Research Letter December 16, 2021 Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection Timothy A. Bates, Savannah K. McBride, Bradie Winders, et al JAMA. 2022;327(2):179-181. doi:10.1001/jama.2021.22898 Breakthrough infections after vaccination against SARS-CoV-2 are increasingly reported, possibly due to waning of vaccine-induced antibody levels.1 Moreover, emerging variants of concern with diminished susceptibility ...

Original Investigation January 11, 2022 Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial Neil A. Goldenberg, John M. Kittelson, Thomas C. Abshire, et al JAMA. 2022;327(2):129-137. doi:10.1001/jama.2021.23182 Abstract Importance  Among patients younger than 21 years of age,...

ORIGINAL ARTICLE Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients Angélica Jayk Bernal, Monica M. Gomes da Silva, Dany B. Musungaie, et al N Engl J Med 2022; 386:509-520DOI: 10.1056/NEJMoa2116044 Abstract BACKGROUND New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coro...